Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) EBIT: 2010-2018

Historic EBIT for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Sep 2018 value amounting to -$13.6 million.

  • EyePoint Pharmaceuticals' EBIT fell 125.67% to -$13.6 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$33.8 million, marking a year-over-year decrease of 94.42%. This contributed to the annual value of -$26.3 million for FY2018, which is 41.44% down from last year.
  • As of Q3 2018, EyePoint Pharmaceuticals' EBIT stood at -$13.6 million, which was down 38.56% from -$9.8 million recorded in Q2 2018.
  • EyePoint Pharmaceuticals' EBIT's 5-year high stood at $20.8 million during Q3 2014, with a 5-year trough of -$13.6 million in Q3 2018.
  • Over the past 3 years, EyePoint Pharmaceuticals' median EBIT value was -$6.0 million (recorded in 2017), while the average stood at -$6.4 million.
  • Per our database at Business Quant, EyePoint Pharmaceuticals' EBIT skyrocketed by 659.14% in 2014 and then crashed by 6,078.72% in 2017.
  • Quarterly analysis of 5 years shows EyePoint Pharmaceuticals' EBIT stood at -$4.1 million in 2014, then declined by 27.26% to -$5.2 million in 2015, then soared by 98.21% to -$94,000 in 2016, then plummeted by 6,078.72% to -$5.8 million in 2017, then tumbled by 125.67% to -$13.6 million in 2018.
  • Its EBIT stands at -$13.6 million for Q3 2018, versus -$9.8 million for Q2 2018 and -$4.7 million for Q1 2018.